​

BioXcel Therapeutics Ownership | Who Owns BioXcel Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

BioXcel Therapeutics Ownership Summary

BioXcel Therapeutics is owned by 0.01% institutional investors, 8.61% insiders, and 91.38% retail investors. Blackrock is the largest institutional shareholder, holding 1.43% of BTAI shares. BSO Bio Santé C is the top mutual fund, with 2.26% of its assets in BioXcel Therapeutics shares.

BTAI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBioXcel Therapeutics0.01%8.61%91.38%
SectorHealthcare Stocks 279.18%10.62%-189.80%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock440.69K1.43%$564.08K
Charles schwab investment management203.62K0.66%$260.63K
Morgan stanley116.56K0.38%$149.20K
Goldman sachs group98.97K0.32%$126.68K
Bank of america corp /de/73.43K0.24%$93.98K
Renaissance77.90K0.18%$29.13K
Thrivent financial for lutherans40.00K0.13%$51.00K
Susquehanna group, llp34.53K0.08%$12.91K
Aqr capital management14.36K0.05%$18.38K
Group one trading18.12K0.04%$6.77M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Thrivent financial for lutherans40.00K0.00%$51.00K
National bank of canada /fi/---
Commonwealth equity services---
Toth financial advisory---
Renaissance77.90K-$29.13K
Engineers gate manager lp---
Legal & general group---
Blackrock440.69K-$564.08K
New york state common retirement fund---
Geode capital management---

Top Buyers

HolderShares% AssetsChange
Goldman sachs group98.97K-76.20K
Bank of america corp /de/73.43K-26.06K
Aqr capital management14.36K-14.36K
Wells fargo & company/mn199.01K-13.95K
Charles schwab investment management203.62K-12.64K

Top Sellers

HolderShares% AssetsChange
Armistice capital---4.32M
Fmr---2.21M
Ubs group---1.28M
Vanguard group---1.19M
Blackrock440.69K--887.38K

New Positions

HolderShares% AssetsChangeValue
Aqr capital management14.36K-14.36K$18.38K
Macquarie group1.05K-1.05K$1.35K

Sold Out

HolderChange
Citigroup-3.00
Nelson, van denburg & campbell wealth management group-4.00
Us bancorp \de\-33.00
Point72 (difc)-35.00
Farther finance advisors-95.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20251-97.92%661-99.99%-0.85%1-94.74%--100.00%
Dec 31, 202413-74.00%537,273-82.68%12.37%4-63.64%6-77.78%
Sep 30, 202450-33.33%3,102,869-68.25%70.73%12-72.73%2750.00%
Jun 30, 202475-2.60%9,773,3755.76%313.15%4451.72%18-28.00%
Mar 31, 202477-9,241,283-1.19%313.11%29-14.71%25-13.79%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BSO Bio Santé C70.00K2.26%-
Vanguard Total Stock Mkt Idx Inv55.39K1.73%-
Fidelity Growth Compy Commingled Pl O469.48K1.15%-425.27K
Vanguard US Total Market Shares ETF886.24K1.01%-1.00
Fidelity Growth Company Fund353.64K0.87%-248.67K
Fidelity Growth Company K6163.94K0.40%-132.22K
Vanguard Institutional Extnd Mkt Idx Tr18.33K0.34%-
Fidelity Extended Market Index14.31K0.26%3.34K
Fidelity Series Growth Company88.26K0.22%-63.60K
NT R2000 Growth Index Fund - NL57.60K0.14%-

Recent Insider Transactions

DateNameRoleActivityValue
Dec 16, 2024O'Neill Vincent See RemarksSell$58.13
Dec 16, 2024Mehta Vimal CEO and PresidentSell$773.36
Dec 16, 2024Mehta Vimal CEO and PresidentSell$357.91
Dec 16, 2024Steinhart Richard I Chief Financial OfficerSell$73.80
Dec 16, 2024Steinhart Richard I Chief Financial OfficerSell$133.18

Insider Transactions Trends

DateBuySell
2025 Q2--
2025 Q1--
2024 Q4-12
2024 Q3-7
2024 Q2-19

BTAI Ownership FAQ

Who Owns BioXcel Therapeutics?

BioXcel Therapeutics shareholders are primarily institutional investors at 0.01%, followed by 8.61% insiders and 91.38% retail investors. The average institutional ownership in BioXcel Therapeutics's industry, Biotech Stocks , is 63.96%, which BioXcel Therapeutics falls below.

Who owns the most shares of BioXcel Therapeutics?

BioXcel Therapeutics’s largest shareholders are Blackrock (440.68K shares, 1.43%), Charles schwab investment management (203.62K shares, 0.66%), and Morgan stanley (116.56K shares, 0.38%). Together, they hold 2.46% of BioXcel Therapeutics’s total shares outstanding.

Does Blackrock own BioXcel Therapeutics?

Yes, BlackRock owns 1.43% of BioXcel Therapeutics, totaling 440.68K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 564.08K$. In the last quarter, BlackRock decreased its holdings by -887K shares, a -66.82% change.

Who is BioXcel Therapeutics’s biggest shareholder by percentage of total assets invested?

Thrivent financial for lutherans is BioXcel Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.00% of its assets in 40K BioXcel Therapeutics shares, valued at 51K$.

Who is the top mutual fund holder of BioXcel Therapeutics shares?

BSO Bio Santé C is the top mutual fund holder of BioXcel Therapeutics shares, with 2.26% of its total shares outstanding invested in 70K BioXcel Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools